Functional (Non Ulcer) Dyspepsia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Signs and symptoms include burning sensation or discomfort in the upper abdomen or lower chest, sometimes relieved by food or antacids, bloating, belching, and nausea. Treatment includes medications to reduce acid production, antibiotics, and low-dose antidepressants.
The Functional (Non-Ulcer) Dyspepsia Drugs in Development market research report provides an overview of the Functional (Non Ulcer) Dyspepsia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Functional (Non-Ulcer) Dyspepsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Functional (Non-Ulcer) Dyspepsia and features dormant and discontinued projects.
What are the targets of the functional dyspepsia pipeline drugs market?
The targets of the functional dyspepsia pipeline drugs market are 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 1, Acetylcholinesterase, Bile Acid, Motilin Receptor, Phosphate, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K.
Functional dyspepsia pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of the functional dyspepsia pipeline drugs market?
The mechanisms of action of the functional dyspepsia pipeline drugs market are 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1 Agonist, Acetylcholinesterase Inhibitor, Bile Acid Sequestrant, Motilin Receptor Agonist, Phosphate Binder, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K Inhibitor.
Functional dyspepsia pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What is the route of administration in the functional dyspepsia pipeline drugs market?
The route of administration in the functional dyspepsia pipeline drugs market is oral.
What are the molecule types in the functional dyspepsia pipeline drugs market?
The molecule types in the functional dyspepsia pipeline drugs market are small molecule and polymer.
Functional dyspepsia pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Which are the key companies in the functional dyspepsia pipeline drugs market?
The key companies in the functional dyspepsia pipeline drugs market are RaQualia Pharma Inc, Daewoong Pharmaceutical Co Ltd, ISOThrive Inc, Mitsubishi Tanabe Pharma Corp, Renexxion LLC, and Zeria Pharmaceutical Co Ltd.
Functional dyspepsia pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report overview
Targets | 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 1, Acetylcholinesterase, Bile Acid, Motilin Receptor, Phosphate, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K |
Mechanisms of Action | 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1 Agonist, Acetylcholinesterase Inhibitor, Bile Acid Sequestrant, Motilin Receptor Agonist, Phosphate Binder, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K Inhibitor |
Route of Administration | Oral |
Molecule Types | Small Molecule and Polymer |
Key Companies | RaQualia Pharma Inc, Daewoong Pharmaceutical Co Ltd, ISOThrive Inc, Mitsubishi Tanabe Pharma Corp, Renexxion LLC, and Zeria Pharmaceutical Co Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Functional (Non-Ulcer) Dyspepsia (Gastrointestinal).
- Reviews of pipeline therapeutics for Functional (Non-Ulcer) Dyspepsia (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Key companies involved in Functional (Non-Ulcer) Dyspepsia (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- Assessment of Functional (Non-Ulcer) Dyspepsia (Gastrointestinal) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Functional (Non-Ulcer) Dyspepsia (Gastrointestinal).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Functional (Non-Ulcer) Dyspepsia (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Functional (Non-Ulcer) Dyspepsia (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
ISOThrive Inc
Mitsubishi Tanabe Pharma Corp
RaQualia Pharma Inc
Renexxion LLC
Zeria Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the functional dyspepsia pipeline drugs market?
The targets of the functional dyspepsia pipeline drugs market are 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 1, Acetylcholinesterase, Bile Acid, Motilin Receptor, Phosphate, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K.
-
What are the mechanisms of action of the Functional dyspepsia pipeline drugs market?
The mechanisms of action of the Functional dyspepsia pipeline drugs market are 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1 Agonist, Acetylcholinesterase Inhibitor, Bile Acid Sequestrant, Motilin Receptor Agonist, Phosphate Binder, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K Inhibitor.
-
What is the route of administration in the Functional dyspepsia pipeline drugs market?
The route of administration in the Functional dyspepsia pipeline drugs market is oral.
-
What are the molecule types in the Functional dyspepsia pipeline drugs market?
The molecule types in the Functional dyspepsia pipeline drugs market are small molecule and polymer.
-
Which are the key companies in the Functional dyspepsia pipeline drugs market?
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.